Thomas Grogan

Thomas Grogan, M.D. is an American professor, pathologist and founder of Ventana Medical Systems, Inc. He currently holds the positions of Professor of Pathology at the University of Arizona College of Medicine and Chief Scientific Officer at Ventana.[1][2]

Thomas Grogan, M.D.
Alma materUniversity of Virginia
George Washington University Medical School
Stanford University
OccupationChief Scientific Officer, Ventana Medical Systems, Inc.
Professor Emeritus of Pathology, University of Arizona College of Medicine

Education

Dr. Grogan received a B.A. in biology from the University of Virginia, and then continued his education at George Washington University Medical School where he earned his M.D. He later completed a post-doctorate, hematopathology fellowship at Stanford University.[1]

Career

Dr. Grogan currently serves as Chief Scientific Officer of Ventana and has served as its Director since founding the company in June 1985. Ventana was subsequently purchased by Roche in 2008 for $3.4 billion.[3] Dr. Grogan also served as Chairman of Ventana from 1985 to 1995.[2]

Dr. Grogan has taught at the University of Arizona College of Medicine since 1979 where he specializes in hematopathology and is now a professor emeritus.[1][2] Among professional associations, he is a Lymphoma Biology Committee member and founding member of the International Lymphoma Study Group (ILSG),[2] which formulated the current classification scheme for clinical practice.[4]

Patents and publications

Dr. Grogan holds the patents for the kinetic-mode process for automated Immunohistochemistry (IHC) and “in situ” hybridization (ISH) staining techniques.[5]

Dr. Grogan has authored or co-authored more than 200 papers on lymphoma and myeloma, including contributing to a World Health Organization (WHO) publication, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, that is part of a series on histological and genetic typing of human tumors that covers all leukemia and lymphoma types.[2] It provides an international standard for oncologists and pathologists for use in the design of studies monitoring response to therapy and clinical outcomes.[6] His 2019 autobiography as to Ventana is a 200 page book, Chasing the Invisible: A Doctor's Quest to Abolish the Last Unseen Cancer Cell.

References
  1. "Thomas Grogan, M.D." University of Arizona. Retrieved 2013-01-31.
  2. "Ventana Appoints Dr. Thomas Grogan Chief Scientific Officer & Medical Director". PR Newswire. Retrieved 2013-01-31.
  3. "Conquering Cancer". BizTucson. Archived from the original on 2013-04-10. Retrieved 2013-01-31.
  4. Pileri, SA; Grogan, TM; Harris, NL; Banks, P; Campo, E; Chan, JK; Favera, RD; Delsol, G; De Wolf-Peeters, C; Falini, B; Gascoyne, RD; Gaulard, P; Gatter, KC; Isaacson, PG; Jaffe, ES; Kluin, P; Knowles, DM; Mason, DY; Mori, S; Müller-Hermelink, HK; Piris, MA; Ralfkiaer, E; Stein, H; Su, IJ; Warnke, RA; Weiss, LM (July 2002). "Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases". Histopathology. 41 (1): 1–29. doi:10.1046/j.1365-2559.2002.01418.x. PMID 12121233. S2CID 32370765.
  5. "Trying to save 8 million people, starting with his wife". Tucson News Now. 2012-10-01. Retrieved 2013-01-31.
  6. Organization, World Health (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours). ISBN 978-9283224310. Missing |author1= (help)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.